Engineering therapeutical extracellular vesicles for clinical translation
Trends in Biotechnology · 2025-01 · 43 (1) · 61-82
DOI: 10.1016/j.tibtech.2024.08.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Biotechnology, 2025-01. Verfasst von Yifan Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Extracellular Vesicles. Die Arbeit wurde bisher 127-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Andrew Sabin Family Foundation, National Institutes of Health.
Abstract (Originalsprache)
Cell-based therapies are revolutionizing medicine by replacing or modifying dysfunctional cells with healthy cells or engineered derivatives, offering disease reversal and cure. One promising approach is using cell-derived extracellular vesicles (EVs), which offer therapeutic benefits similar to cell transplants without the biosafety risks. Although EV applications face challenges like limited production, inadequate therapeutic loading, and poor targeting efficiency, recent advances in bioengineering have enhanced their effectiveness. Herein, we summarize technological breakthroughs in EV bioengineering over the past 5 years, highlighting their improved therapeutic functionalities and potential clinical prospects. We also discuss biomanufacturing processes, regulation, and safety considerations for bioengineered EV therapies, emphasizing the significance of establishing robust frameworks to ensure translation capability, safety, and therapeutic effectiveness for successful clinical adoption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- School of Life Sciences, Jilin University, Changchun, China.
- Peking University Shenzhen Graduate School, Shenzhen, China; Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China.
- Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: bykim@mdanderson.org.
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: wjiang4@mdanderson.org.
Förderung
- NCI NIH HHS
- Andrew Sabin Family Foundation
- National Institutes of Health
Zitieren
APA
Ma, Y., Dong, S., Grippin, A. J., Teng, L., Lee, A. S., Kim, B. Y. S., & Jiang, W. (2025). Engineering therapeutical extracellular vesicles for clinical translation. Trends in Biotechnology, 43(1), 61-82. https://doi.org/10.1016/j.tibtech.2024.08.007
Vancouver
Ma Y, Dong S, Grippin AJ, Teng L, Lee AS, Kim BYS, et al. Engineering therapeutical extracellular vesicles for clinical translation. Trends in Biotechnology. 2025;43(1):61-82. doi:10.1016/j.tibtech.2024.08.007
BibTeX
@article{Ma2025,
author = {Ma, Yifan and Dong, Shiyan and Grippin, Adam J and Teng, Lesheng and Lee, Andrew S and Kim, Betty Y S and Jiang, Wen},
title = {Engineering therapeutical extracellular vesicles for clinical translation},
journal = {Trends in Biotechnology},
year = {2025},
volume = {43},
number = {1},
pages = {61--82},
doi = {10.1016/j.tibtech.2024.08.007}
}
EUVIMED